sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
result
sever
acut
respiratori
diseas
pneumonia
sometim
death
diseas
report
guangdong
provinc
china
spread
nation
within
month
diseas
sever
link
age
comorbid
mortal
rate
increas
age
exceed
individu
sarscov
zoonot
viru
cross
speci
barrier
like
origin
bat
speci
includ
civet
raccoon
dog
domest
cat
swine
rodent
new
zoonot
variant
may
emerg
evidenc
sporad
case
human
diseas
late
earli
aros
strain
distinct
epidem
sever
laboratoryacquir
infect
report
includ
secondari
spread
result
fatal
diseas
given
signific
health
econom
impact
develop
effect
vaccin
strategi
protect
epidem
zoonot
sarscov
strain
highli
desir
attenu
kill
sarscov
dna
viral
vector
vaccin
evalu
number
anim
model
includ
mous
ferret
hamster
primat
demonstr
sarscov
spike
glycoprotein
princip
compon
protect
immun
although
strong
immun
respons
elicit
glycoprotein
nucleocapsid
n
protein
passiv
transfer
studi
illustr
anti
antibodi
confer
protect
sarscov
replic
mous
model
vaccin
develop
face
seri
potenti
concern
includ
revers
recombin
repair
attenu
vaccin
strain
induct
immunemedi
enhanc
patholog
wane
immun
protect
lack
crossprotect
heterolog
strain
limit
vaccin
efficaci
within
senesc
popul
furthermor
immun
enhanc
demonstr
anoth
coronaviru
felin
infecti
periton
coronaviru
recent
modifi
vaccinia
vector
express
sarss
exacerb
hepat
ferret
fail
protect
infect
notabl
antibodi
epidem
urbani
strain
increas
infect
lentivirus
pseudotyp
anim
sarss
glycoprotein
vitro
model
rais
specter
vaccinemedi
immun
enhanc
diseas
follow
heterotyp
challeng
anoth
potenti
problem
sar
vaccin
might
fail
induc
antibodi
protect
infect
diverg
strain
sarscov
glycoprotein
sarscov
contain
amino
acid
variat
zoonot
epidem
strain
possibl
limit
effect
monotyp
sarss
vaccin
final
studi
measur
durat
protect
immun
vaccin
efficaci
anim
greater
mo
postboost
yet
report
report
efficaci
venezuelan
equin
enceph
viru
replicon
particl
vrp
vaccin
express
urbani
sarscov
glycoprotein
vrp
n
protein
vrpn
either
individu
combin
vrpsn
determin
young
senesc
mous
model
test
whether
senesc
mous
model
exhibit
agerel
suscept
sarscov
similar
seen
human
diseas
provid
sensit
measur
vaccin
efficaci
reveal
potenti
complic
sarscov
vaccin
develop
vulner
elderli
popul
evalu
durat
protect
immun
follow
homolog
heterolog
sar
viru
challeng
examin
impact
wane
immun
longterm
protect
use
publicli
avail
sarscov
sequenc
databas
bioinformat
approach
synthet
biolog
revers
genet
construct
viabl
heterolog
challeng
viru
test
abil
current
vaccin
regimen
protect
zoonot
strain
like
sourc
futur
epidem
urbani
recombin
urbani
icsar
recombin
chimer
viru
encod
gene
sarscov
strain
propag
cell
eagl
mem
supplement
fetal
calf
serum
kanamycin
gentamycin
humidifi
incub
viru
growth
cultur
cell
infect
multipl
infect
moi
h
monolay
wash
twice
ml
pb
overlaid
complet
mem
viru
sampl
harvest
differ
time
postinfect
titer
plaqu
assay
plaqu
visual
neutral
red
stain
count
human
nasal
tracheobronchi
epitheli
cell
obtain
airway
specimen
reject
patient
undergo
elect
surgeri
univers
north
carolina
unc
institut
review
protocol
unc
cystic
fibrosi
cf
center
tissu
cultur
core
briefli
primari
cell
expand
plastic
gener
passag
cell
plate
densiti
cell
per
well
permeabl
transwellcol
tcol
diamet
corn
http
wwwcorningcom
support
human
airway
epithelium
hae
cultur
gener
provis
interfac
wk
form
welldifferenti
polar
cultur
resembl
vivo
pseudostratifi
mucosciliari
epithelium
infect
wildtyp
recombin
sarscov
previous
describ
laboratori
viru
work
perform
biolog
safeti
cabinet
bsc
cabinet
biosafeti
level
three
laboratori
contain
redund
hepafilt
exhaust
fan
personnel
doubl
glove
wore
tyvek
suit
hood
suppli
hepafilt
air
power
airpurifi
respir
papr
glycoprotein
sequenc
report
synthet
dna
contain
mutat
purchas
blue
heron
biotechnolog
http
wwwblueheronbiocom
insert
sars
fragment
plasmid
clone
sars
fulli
sequenc
shown
contain
appropri
mutat
remain
mutat
incorpor
pcr
mutagenesi
amplicon
amplicon
amplicon
b
amplicon
b
cataaattggatccattgctgg
follow
seamless
ligat
amplicon
previous
describ
sarsf
subclon
final
construct
sarsf
fulli
sequenc
found
contain
appropri
set
glycoprotein
allel
gener
previous
describ
infecti
clone
fragment
plasmid
dna
prepar
escherichia
coli
invitrogen
http
wwwinvitrogencom
isol
purifi
qiagen
http
wwwqiagencom
infecti
clone
fragment
b
c
e
digest
bgli
infecti
clone
fragment
f
digest
ecori
noti
respect
infecti
clone
fragment
f
dephosphoryl
digest
bgli
individu
cdna
fragment
gel
purifi
qiagen
ligat
roch
http
wwwrochecom
form
fulllength
genom
cdna
chloroform
extract
etoh
precipit
n
cdna
fulllength
viral
genom
cdna
use
templat
vitro
transcript
reaction
ambion
http
wwwambioncom
n
fulllength
viral
genom
transcript
electropor
vero
cell
cell
cultur
media
contain
viru
harvest
h
postelectropor
viru
plaqu
purifi
passag
twice
vero
cell
result
stock
plaqu
titer
cyropreserv
twelv
hour
postinfect
cell
wash
pb
lyse
buffer
contain
mm
trishcl
ph
mm
nacl
deoxycholin
sd
postnuclear
supernat
ad
equal
volum
mm
sd
result
final
sd
concentr
sampl
heat
inactiv
min
prior
remov
sampl
heat
inactiv
min
use
equival
sampl
volum
load
onto
criterion
gradient
gel
biorad
http
wwwbioradcom
transfer
pvdf
membran
biorad
blot
probe
polyclon
mous
antisera
direct
urbani
glycoprotein
dilut
convalesc
human
sera
dilut
develop
use
electrogener
chemiluminesc
ecl
reagent
amersham
bioscienc
http
patient
infect
second
diseas
outbreak
toronto
canada
one
hundr
plaqueform
unit
pfu
either
icsarscov
treat
heatinactiv
serum
dilut
final
concentr
incub
min
result
titer
determin
plaqu
assay
plaqu
number
form
viru
treat
dilut
sera
individu
mice
vaccin
vrp
vrpsn
compar
averag
number
plaqu
form
treatment
given
dilut
sera
vrp
express
influenza
ha
protein
vrpha
pbsvaccin
mice
express
rel
percentag
dilut
plaqu
neutral
determin
anim
femal
balbc
mice
charl
river
laboratori
http
wwwcrivercom
anesthet
ketamin
mgmous
xylazin
mgmous
mixtur
administ
intraperiton
volum
mous
intranas
inocul
viru
concentr
pfuml
viru
four
day
postinfect
right
lung
remov
frozen
later
plaqu
assay
determin
viral
titer
half
left
lung
place
trizol
reagent
invitrogen
rna
extract
second
half
left
lung
fix
pfa
pb
ph
least
prior
paraffin
imbed
section
histopatholog
analysi
mice
hous
steril
condit
sentinel
mice
use
verifi
coloni
mous
hepat
viru
mhv
neg
experiment
protocol
review
approv
institut
anim
care
use
committe
unc
chapel
hill
young
mice
refer
challeng
sarscov
age
equal
less
mo
old
wherea
old
senesc
mice
anim
age
greater
time
challeng
lung
weigh
homogen
four
equival
volum
pb
gener
solut
solut
centrifug
rpm
tabletop
centrifug
min
clarifi
supernat
serial
dilut
pb
volum
dilut
place
onto
monolay
vero
cell
dish
follow
incub
cell
overlaid
agarosecontain
medium
two
day
later
plate
stain
neutral
red
plaqu
count
vrp
construct
made
two
round
pcr
first
gener
two
amplicon
second
round
overlap
pcr
fuse
togeth
fuse
dna
digest
apai
asci
ligat
similarli
digest
plasmid
pcr
reaction
perform
expand
long
taq
roch
molecular
biochem
http
wwwrocheappliedsciencecom
cycl
extens
min
first
amplicon
use
construct
vrp
vrpn
gener
primer
use
templat
amplicon
produc
use
primer
sarsf
plasmid
templat
amplicon
made
use
ligat
sars
f
fragment
vrp
vrpn
cdna
templat
sequenc
verif
replicon
particl
produc
previous
describ
mice
vaccin
infecti
unit
iu
vrp
volum
left
rear
footpad
lung
fix
pfa
pb
submit
histopatholog
core
facil
unc
chapel
hill
paraffin
imbed
section
thick
hematoxylin
eosin
stain
approxim
onequart
total
lung
section
four
six
section
mount
cut
taken
five
differ
depth
within
paraffinimbed
tissu
lung
patholog
score
blind
manner
six
ten
section
per
anim
evalu
score
use
follow
scale
mild
inflamm
mild
moder
inflamm
moder
sever
inflamm
less
half
tissu
section
sever
inflamm
half
tissu
section
set
tissu
also
evalu
qualit
respiratori
pathologist
author
jh
paraffinembed
section
probe
utplabel
riboprob
complementari
n
gene
sarscov
urbani
ha
gene
strain
influenza
neg
control
use
previous
describ
method
brief
follow
treatment
prevent
nonspecif
probe
bind
tissu
incub
overnight
either
probe
hybrid
buffer
slide
wash
dehydr
coat
nbt
emuls
kodak
http
wwwkodakcom
incub
wk
prior
develop
posit
signal
determin
silver
grain
deposit
evalu
antibodi
titer
determin
standard
indirect
enzymelink
immunosorb
assay
elisa
highbind
roundbottom
plate
corn
http
wwwcorningcom
coat
sarss
sarsn
inactiv
influenza
dilut
carbon
buffer
contain
mm
sodium
carbon
mm
sodium
bicarbon
ph
overnight
mous
sera
dilut
casein
block
buffer
sigma
http
wwwsigmaaldrichcom
ad
well
duplic
serial
dilut
perform
follow
incub
h
plate
incub
h
goat
antimous
igg
alkalin
phosphatas
ap
conjug
sigma
develop
pnitrophenyl
phosphat
pnpp
sigma
optic
densiti
od
nm
measur
biorad
model
micropl
reader
halfmaximum
elisa
titer
calcul
sigmaplot
systat
http
wwwsystatcom
use
solut
sigmoid
line
plot
log
reciproc
dilut
mous
sera
result
absorb
determin
log
reciproc
dilut
absorb
achiev
sinc
low
amount
antibodi
measur
passiv
transfer
experi
od
elisa
titer
calcul
mice
inocul
iu
vrpha
vrp
vrpn
wk
age
boost
wk
later
termin
bled
via
cardiac
punctur
wk
postboost
sera
group
pool
transfer
tail
vein
inject
mice
wk
age
mice
receiv
sera
bled
challeng
pfu
icsar
unless
otherwis
note
twotail
mannwhitney
test
use
statist
comparison
fisher
exact
test
complet
compar
number
anim
posit
viral
replic
within
lung
group
anim
vaccin
vrp
vrpsn
neg
control
group
vrpha
pb
valu
outsid
limit
detect
assign
valu
equal
limit
detect
analysi
plu
minu
symbol
use
refer
standard
deviat
amino
acid
multipl
align
gener
entir
gene
viral
sequenc
repres
earli
middl
late
phase
sar
epidem
human
well
anim
strain
sarscov
isol
civet
racoon
dog
found
chines
live
anim
market
hous
farm
china
suppli
market
sequenc
align
use
clustalx
default
set
phylogenet
tree
gener
use
bayesian
infer
implement
program
mrbay
briefli
align
export
nexu
format
amino
acid
substitut
model
set
jtt
use
lset
command
markov
chain
mont
carlo
simul
use
approxim
posterior
probabl
tree
sampl
conduct
four
chain
gener
tree
sampl
everi
gener
tree
collect
summar
sumt
command
set
burnin
gener
consensu
tree
use
major
rule
burnin
valu
determin
use
sump
command
arbitrari
burnin
demonstr
stationar
occur
prior
gener
indic
burnin
appropri
sumt
command
sarscov
glycoprotein
gene
n
protein
gene
pcr
clone
sequenc
verifi
insert
venezuelan
equin
enceph
vrp
vrp
vrpn
construct
packag
give
titer
greater
iu
per
ml
shown
express
antigen
relev
recombin
protein
vrpinfect
cell
lysat
probe
antiserum
deriv
convalesc
human
sar
patient
western
blot
analysi
lysat
reveal
expect
glycoprotein
doublet
approxim
kda
wherea
lysat
reveal
major
product
less
kda
expect
size
sarss
n
respect
figur
vrp
inocul
balbc
mice
test
abil
induc
antigenspecif
antibodi
western
blot
perform
vero
cell
lysat
infect
urbani
sarscov
icsarscov
urbani
recombin
viru
chimer
sarscov
express
glycoprotein
heterolog
strain
blot
probe
mous
serum
human
convalesc
serum
mous
serum
western
blot
demonstr
probe
human
serum
resolv
band
correspond
major
sar
antigen
doublet
kda
n
triplet
kda
well
unidentifi
sarscov
protein
figur
serum
mice
vaccin
vrp
identifi
sarss
figur
wherea
serum
mice
vaccin
vrpn
recogn
sarsn
addit
anoth
sarscov
protein
probabl
dimer
n
figur
gener
measur
vaccin
efficaci
tabl
experi
six
balbc
mice
vaccin
either
iu
vrp
vrpha
boost
wk
later
equal
amount
vrp
challeng
pfu
icsarscov
wk
postboost
consist
studi
made
use
vector
vaccin
induc
protect
respons
vaccin
vrp
also
prevent
replic
icsarscov
follow
challeng
viru
detect
plaqu
assay
pfug
limit
detect
lung
anim
postinfect
wherea
mous
lung
mean
titer
pfug
figur
vaccin
vrp
demonstr
signific
protect
time
peak
lung
titer
rel
control
anim
p
fisher
exact
test
second
vaccin
experi
complet
evalu
longterm
vrp
protect
fiveweekold
balbc
mice
vaccin
iu
vrpha
vrp
vrpn
combin
vrp
vrpn
vrpsn
boost
wk
later
fiftyfour
week
postboost
mice
challeng
pfu
icsarscov
lung
remov
postinfect
summar
tabl
experi
although
day
postchalleng
demonstr
peak
viral
titer
day
chosen
harvest
lung
time
highest
level
patholog
evid
senesc
mice
titer
lung
figur
anim
vaccin
vrp
combin
vrpsn
limit
detect
pfug
contrast
lung
titer
anim
pfug
compar
anim
titer
pfug
p
plaqu
assay
result
confirm
situ
hybrid
lung
tissu
infect
mice
figur
radiolabel
riboprob
complementari
sarscov
n
gene
hybrid
section
lung
five
mice
vrpha
vrpn
vrp
vrpsn
vaccin
group
lung
section
vrpha
unpublish
data
vrpn
figur
imag
vaccin
anim
exhibit
extens
situ
signal
arrow
wherea
one
five
section
figur
imag
b
zero
five
section
figur
imag
c
mice
exhibit
sarscov
nspecif
signal
vrp
combin
vrpsn
provid
complet
longterm
protect
challeng
homolog
vaccin
strain
sarscov
postinfect
p
fisher
exact
test
vrp
group
rel
vrpha
perform
crossprotect
efficaci
studi
necessari
construct
heterolog
sarscov
select
like
candid
strain
made
bayesian
analysi
sarscov
glycoprotein
demonstr
three
main
phylogenet
branch
two
branch
includ
virus
isol
anim
palm
civet
raccoon
dog
low
pathogen
virus
sporad
isol
human
repres
earli
middl
late
phase
epidem
strain
form
third
branch
sarss
phylogenet
tree
figur
resurrect
glycoprotein
viru
report
sporad
sar
case
decemb
although
success
isol
glycoprotein
sequenc
report
compar
epidem
strain
like
repres
independ
introduct
report
less
pathogen
glycoprotein
sequenc
among
diverg
human
strain
glycoprotein
contain
amino
acid
chang
rel
urbani
figur
mani
map
within
neutral
epitop
amino
acid
part
receptor
bind
domain
rbd
importantli
polyclon
antibodi
direct
latephas
urbani
strain
less
effect
neutral
pseudotyp
virus
bear
glycoprotein
bear
urbani
urbani
glycoprotein
remov
sarscov
molecular
clone
replac
synthet
cdna
encod
sequenc
use
gener
recombin
viru
sequenc
analysi
plaquepurifi
recombin
viru
confirm
presenc
glycoprotein
two
addit
chang
gene
rel
urbani
like
aros
tissuecultur
adapt
chimer
differ
urbani
sarscov
glycoprotein
wildtyp
icsarscov
recombin
virus
replic
vero
cell
compar
titer
approach
pfuml
within
h
unpublish
data
protein
detect
western
blot
human
antiserum
convalesc
patient
figur
given
reduc
amount
n
present
lysat
cell
reduc
intens
band
probe
either
mous
sera
convalesc
human
serum
like
due
presenc
lower
protein
rather
mark
differ
antibodi
specif
urbani
replic
effici
hae
cell
although
maximum
titer
approxim
log
lower
icsar
urbani
figur
compar
growth
icsar
anim
balbc
mice
infect
pfu
either
icsar
postinfect
icsarscov
mean
lung
titer
pfug
wherea
titer
lower
pfug
p
mean
lung
titer
mice
day
pfug
compar
titer
p
seventh
day
viru
replic
lung
three
five
mice
infect
icsarscov
four
five
mice
infect
fell
limit
detect
pfug
averag
icsarscov
titer
similar
day
pfug
pfug
p
respect
figur
evalu
vrp
protect
shortterm
heterolog
challeng
group
eight
anim
prime
wk
age
iu
vrp
vrpn
vrpsn
vrpha
boost
wk
later
challeng
wk
postboost
pfu
summar
tabl
experi
lung
harvest
challeng
vrp
vrpsn
protect
p
fisher
exact
test
vrp
vrpsn
group
rel
vrpha
heterolog
recombin
viru
replic
figur
although
high
titer
viru
detect
mockvaccin
anim
mean
titer
pfug
respect
anim
lower
mean
titer
p
sarscov
vaccin
confer
protect
elderli
subject
face
infect
new
variant
viru
model
scenario
vaccin
balbc
retir
breeder
iu
vrp
vrpn
vrpsn
pb
boost
wk
later
challeng
wk
postboost
pfu
summar
tabl
experi
postinfect
mean
titer
lung
anim
vaccin
vrpn
pb
similar
pfug
p
respect
figur
vrp
vaccin
provid
partial
protect
compar
pb
control
group
p
fisher
exact
test
lung
three
eight
anim
posit
viral
replic
mean
titer
pfug
eight
lung
harvest
anim
posit
viral
replic
although
mean
titer
pfug
compar
mean
titer
mice
p
reduc
rel
pb
control
p
presenc
sarscov
replic
lung
control
vaccin
anim
confirm
situ
hybrid
figur
sarscov
nspecif
riboprob
hybrid
lung
section
mice
pb
group
figur
test
lung
section
pb
mock
unpublish
data
figur
imag
anim
exhibit
situ
signal
arrow
although
signal
appear
intens
anim
figur
lung
anim
figur
imag
b
two
five
slide
exhibit
signal
background
level
wherea
vrpsn
figur
imag
c
three
four
slide
neutral
antibodi
report
confer
protect
sarscov
replic
within
lung
mice
interest
determin
whether
vrp
vaccin
establish
high
neutral
antibodi
level
persist
challeng
plaqu
reduct
neutral
titer
prnt
serum
sampl
harvest
prior
vaccin
show
neutral
icsarscov
similar
result
note
serum
collect
mice
vaccin
neg
control
vrpha
pb
unpublish
data
prnt
valu
dilut
serum
plaqu
number
reduc
rel
viru
treat
control
sera
anim
wk
postboost
icsarscov
compar
figur
tabl
mean
reciproc
dilut
vrp
vrpsn
icsar
measur
wk
postboost
wk
sera
mice
vaccin
combin
vrpsn
mean
reciproc
wk
respect
initi
neutral
respons
anim
vaccin
vrp
vrpsn
similar
p
wk
postboost
although
signific
wane
icsarsneutr
activ
period
anim
p
wilcoxin
match
pair
signedrank
test
vrpsn
serum
diminish
p
wilcoxin
match
pair
signedrank
test
test
sera
remain
lower
limit
detect
suffici
prevent
icsar
replic
within
lung
challeng
anim
figur
neutral
activ
sera
vaccin
anim
effect
vaccin
strain
heterolog
viru
sera
harvest
vaccin
combin
reciproc
dilut
vrp
sampl
wk
postboost
limit
detect
wherea
two
sampl
week
bleed
measur
limit
detect
mean
valu
measur
vrpsn
week
postboost
limit
detect
one
except
time
point
one
mous
measur
wk
averag
titer
anoth
wk
postboost
averag
given
vrp
vaccin
abil
provid
longterm
protect
like
due
strong
respons
induc
vaccin
mice
measur
vrp
immun
sera
mice
vaccin
old
tabl
experi
determin
incomplet
protect
seen
studi
could
link
reduc
neutral
antibodi
respons
senesc
anim
figur
tabl
vaccin
strain
reciproc
dilut
mean
two
six
sampl
fall
limit
detect
vrp
mice
wk
wk
postboost
four
six
fall
limit
detect
sera
mice
valu
fall
near
limit
detect
one
measur
sampl
averag
icsarsneutr
abil
detect
week
vrp
valu
limit
detect
except
singl
anim
show
neutral
titer
wk
postboost
averag
dilut
group
sera
harvest
anim
exhibit
mark
reduct
neutral
abil
compar
respons
anim
vaccin
young
even
vaccin
strain
p
vrp
week
versu
vpp
week
postboost
p
vrpsn
week
versu
vrpsn
week
postboost
strong
neutral
respons
induc
vrp
vaccin
administ
senesc
mice
elisa
total
igg
specif
sarss
influenzaha
perform
compar
vrp
vaccin
abil
induc
antibodi
antigen
mice
vaccin
young
senesc
elisa
sarss
perform
sera
collect
prechalleng
mice
experi
figur
mice
vaccin
young
vrp
experi
averag
halfmaximum
elisa
titer
wk
postboost
wherea
senesc
anim
approxim
log
lower
week
postboost
p
differ
anim
two
age
group
even
strike
anti
igg
level
compar
vrpsn
mice
anim
vaccin
young
vrpsn
averag
titer
wherea
averag
senesc
anim
limit
detect
halfmaximum
elisa
titer
verifi
reduc
abil
senesc
anim
mount
specif
antibodi
respons
limit
sarss
antigen
antiha
igg
titer
compar
mice
vaccin
vrpha
averag
antiha
titer
anim
vaccin
young
wherea
titer
vaccin
senesc
mice
approxim
onetenth
size
mean
titer
p
reduc
abil
sera
harvest
senesc
anim
neutral
viru
correl
gener
reduct
antigenspecif
antibodi
product
lung
vaccin
senesc
mice
challeng
studi
tabl
experi
section
hematoxylin
eosin
stain
analyz
patholog
though
animaltoanim
variat
gener
minor
inflammatori
chang
observ
senesc
control
mice
challeng
either
icsar
figur
howev
follow
sarscov
challeng
senesc
mice
nvaccin
group
exhibit
mark
bronchiol
alveol
well
conspicu
perivascular
peribronchiolar
interstiti
accumul
numer
mononuclear
leukocyt
mainli
lymphocyt
plasma
cell
ie
lymphoplasmacyt
cuf
increas
number
wide
scatter
eosinophil
figur
upon
sarscov
challeng
anim
vaccin
sn
also
exhibit
similar
less
sever
lymphoplasmacyt
infiltr
around
pulmonari
vessel
bronchiolar
airway
although
alveol
eosinophil
infiltr
promin
featur
anim
figur
lung
anim
vaccin
vrp
similar
pb
mockvaccin
anim
minim
lymphoplasmacyt
cell
accumul
figur
therefor
n
vaccin
fail
control
sarscov
replic
within
lung
n
vaccin
also
result
enhanc
immunopatholog
lung
senesc
anim
upon
viral
challeng
order
determin
kinet
immunopatholog
whether
effect
age
depend
young
old
mice
challeng
icsar
sacrif
day
postchalleng
young
wk
age
senesc
wk
age
femal
balbc
mice
vaccin
iu
vrpn
vrpha
boost
wk
later
challeng
pfu
icsarscov
wk
postboost
lung
harvest
day
titer
process
histolog
summar
tabl
experi
young
mice
day
averag
lung
titer
pfug
pfug
anim
respect
day
averag
titer
pfug
pfug
mice
sar
titer
mice
lung
drop
limit
detect
day
two
three
lung
mice
show
measur
titer
mean
pfug
day
viru
undetect
either
group
senesc
anim
day
averag
lung
titer
pfug
anim
respect
day
mean
titer
drop
pfug
anim
pfug
vrpha
control
day
one
mous
detect
titer
pfug
wherea
lung
two
mice
posit
replic
titer
pfug
viru
detect
either
group
day
though
enhanc
inflamm
observ
subset
anim
day
figur
inflammatori
infiltr
readili
appar
young
senesc
anim
day
postinfect
figur
unpublish
data
maintain
day
postinfect
figur
note
previous
anim
also
differ
presenc
eosinophil
figur
day
postinfect
eosinophil
rare
seen
either
mice
figur
respect
anim
anim
eosinophil
widespread
day
figur
larg
clear
lung
day
figur
appar
differ
sever
young
senesc
anim
suggest
immun
patholog
specif
preexist
n
immun
age
depend
unpublish
data
passiv
transfer
antin
antiha
anti
sera
naiv
mice
perform
determin
increas
inflammatori
respons
could
attribut
nspecif
antibodi
confirm
protect
svaccin
anim
mediat
sspecif
antibodi
hyperimmun
sera
vrpha
od
elisa
titer
vrpn
od
elisa
titer
vrp
od
elisa
titer
intraven
transfer
volum
group
naiv
balbc
mice
prior
challeng
pfu
icsar
prior
challeng
serum
collect
mice
antigenspecif
igg
titer
verifi
success
transfer
young
mice
receiv
n
mean
elisa
serum
titer
od
wherea
senesc
mice
n
od
elisa
titer
averag
serum
titer
mice
inject
od
elisa
titer
young
n
od
elisa
titer
senesc
anim
n
od
elisa
titer
young
anim
n
senesc
mice
n
lung
harvest
postchalleng
viru
titer
determin
process
histolog
analysi
viru
titer
young
mice
pfug
group
anti
vrpn
group
limit
detect
pfug
anim
inject
titer
senesc
mice
pfug
group
anim
receiv
limit
detect
mice
inocul
none
mice
display
enhanc
inflamm
note
anim
unpublish
data
indic
observ
immunopatholog
result
antibodydepend
enhanc
vrp
vaccin
vector
induc
robust
mucos
cellular
immun
respons
larg
number
foreign
antigen
evalu
candid
vaccin
homolog
zoonot
sarscov
challeng
young
senesc
anim
inocul
mice
vrp
induc
antibodi
recogn
epidem
sarscov
glycoprotein
well
highli
diverg
strain
vrp
vaccin
induc
longterm
protect
challeng
vaccin
strain
complet
shortterm
protect
challeng
partial
protect
diverg
viru
senesc
mous
model
contrast
vaccin
vrpn
fail
inhibit
viral
replic
within
lung
either
young
senesc
anim
result
enhanc
immunopatholog
follow
viral
challeng
provid
measur
benefit
combin
vrp
data
suggest
vaccin
regimen
elicit
complet
protect
antigen
heterolog
form
sarscov
healthi
individu
may
suffici
higher
risk
group
includ
vulner
elderli
popul
need
test
candid
vaccin
induc
antin
respons
vrp
vaccin
gener
strong
neutral
antibodi
respons
persist
year
provid
complet
protect
challeng
vaccin
strain
human
neutral
titer
measur
geometr
mean
titer
studi
evalu
inactiv
viru
vaccin
neutral
antibodi
titer
greater
result
complet
protect
challeng
mice
inocul
vesicular
stomat
viru
vector
express
sarss
develop
lower
averag
neutral
titer
nevertheless
protect
sarscov
infect
mo
vaccin
follow
anim
boost
knowledg
first
assay
illustr
wane
immun
respons
sarscov
candid
vaccin
averag
mice
vaccin
young
vrp
show
signific
reduct
neutral
titer
wk
postboost
wherea
mice
vaccin
combin
vrpsn
experienc
reduct
period
time
although
problemat
compar
neutral
antibodi
titer
induc
sar
vaccin
due
use
differ
assay
demonstr
protect
challeng
either
vaccin
heterolog
challeng
viru
strain
anim
icsar
greater
near
assay
limit
detect
vaccin
induc
robust
neutral
titer
homolog
strain
like
confer
protect
zoonot
reintroduct
especi
younger
popul
report
dna
vector
vaccin
vrpn
protect
mice
sarscov
replic
benefit
vaccin
cocktail
vrp
vrpn
observ
although
approxim
halflog
reduct
viral
titer
within
lung
mice
occasion
observ
although
reduct
sarscov
titer
interpret
posit
aspect
potenti
vaccin
given
relationship
viral
titer
sar
diseas
sever
increas
number
lymphocyt
eosinophil
inflammatori
infiltr
also
characterist
immun
patholog
observ
respiratori
syncyti
viru
rsv
infect
follow
vaccin
formalininactiv
rsv
rais
concern
vaccin
n
alon
fail
effect
protect
sarscov
replic
may
result
vaccineenhanc
pulmonari
diseas
ninduc
patholog
previous
report
probabl
studi
examin
young
mice
postinfect
prior
infiltr
inflammatori
cell
lung
patholog
clearli
evid
day
persist
wk
follow
wildtyp
viru
challeng
suggest
potenti
seriou
complic
lung
physiolog
function
find
particular
signific
sarsn
inactiv
sarscov
vaccin
current
develop
also
induc
antin
antibodi
cell
respons
may
lead
advers
effect
therefor
caution
merit
respect
inclus
sarscov
n
protein
vaccin
formul
passiv
transfer
antin
antibodi
contribut
inflamm
lead
us
hypothes
activ
cell
absenc
effect
neutral
antibodi
mediat
advers
respons
interest
cytokin
profil
hallmark
rsv
vaccineenhanc
diseas
rais
possibl
nspecif
immun
respons
skew
similar
manner
sarscov
strain
divers
mostli
confin
china
mani
human
anim
isol
success
cultur
vitro
consequ
avail
experiment
strain
like
urbani
nearli
ident
reflect
natur
divers
recent
advanc
synthet
biolog
use
reconstruct
extinct
virus
specif
gene
virus
de
novo
nucleotid
sequenc
provid
mean
expand
number
avail
sarscov
test
strain
use
comprehens
sarscov
genet
databas
resurrect
diverg
glycoprotein
urbani
genet
backbon
recombin
viru
ident
molecular
clone
except
presenc
two
mutat
like
evolv
transfect
fulllength
rna
viru
passag
vero
cell
similar
cell
cultur
adapt
report
sarscov
strain
isol
human
clinic
specimen
passag
vitro
cov
sequenc
diverg
urbani
effici
vitro
replic
hae
vero
cultur
robust
vivo
replic
mous
model
make
excel
heterolog
challeng
inoculum
vaccin
studi
rbd
also
present
mani
zoonot
isol
describ
civet
raccoon
dog
support
use
zoonot
model
strain
furthermor
reduc
replic
hae
cultur
compar
urbanicov
consist
reduc
pathogenesi
note
human
case
consist
previou
work
compar
suscept
pseudotyp
lentivirus
bear
glycoprotein
variou
sar
strain
neutral
anti
urbani
igg
antibodi
demonstr
reduc
neutral
rel
vaccin
strain
spite
vrp
vaccin
success
provid
shortterm
protect
diverg
viru
vaccin
senesc
anim
produc
significantli
reduc
antibodi
respons
compar
younger
mice
challeng
heterolog
viru
protect
incomplet
howev
anim
valu
icsar
show
reduc
viral
replic
within
lung
follow
challeng
either
vaccin
strain
note
homolog
challeng
studi
combin
vrpsn
enhanc
protect
heterolog
challeng
may
actual
weaken
senesc
anim
show
even
lower
anti
antibodi
respons
even
higher
rate
viral
replic
albeit
reduc
titer
increas
lung
patholog
one
possibl
caus
vaccin
failur
emerg
escap
mutant
environ
suboptim
neutral
howev
initi
data
compar
neutral
suscept
virus
isol
mice
challeng
stock
refut
conjectur
unpublish
data
incomplet
protect
vaccin
immunosenesc
anim
human
well
document
like
result
agerel
compromis
one
stage
immun
respons
vaccin
instanc
antibodi
respons
immunosenesc
tend
offer
less
protect
limit
switch
secondari
isotyp
lower
antibodi
level
gener
product
antibodi
lower
affin
although
test
singlevaccin
dose
regimen
previou
studi
demonstr
efficaci
sarscov
challeng
young
anim
given
low
antibodi
titer
follow
boost
senesc
popul
singlevaccin
dose
formul
like
prove
ineffect
rather
improv
vrp
efficaci
older
vaccine
may
requir
addit
vaccin
boost
use
adjuv
addit
therapi
anoth
like
contribut
factor
vaccin
failur
older
anim
resist
neutral
rel
vaccin
strain
icsarscov
least
three
neutral
site
identifi
sarscov
glycoprotein
two
map
nterminu
rbd
glycoprotein
one
weak
third
site
near
carboxyterminu
given
mutat
map
around
nterminu
rbd
possibl
either
one
critic
epitop
significantli
differ
like
explain
resist
neutral
antisera
urbani
data
suggest
robust
neutral
titer
induc
candid
vaccin
provid
longterm
protect
sarscov
infect
especi
vulner
senesc
popul
heterolog
strain
earlier
work
indic
antibodi
urbani
strain
sarscov
enhanc
vitro
infect
pseudotyp
virus
bear
glycoprotein
zoonot
strain
primarili
strain
rais
specter
complic
newli
emerg
strain
contrast
shown
monoclon
polyclon
antibodi
neutral
epidem
strain
may
enhanc
infect
pseudotyp
virus
bear
glycoprotein
although
enhanc
infect
margin
best
research
antibodi
direct
urbani
indic
polyclon
antibodi
neutral
vero
cell
although
less
effici
vaccin
strain
consist
previou
report
moreov
young
senesc
mous
model
anim
challeng
homolog
heterolog
recombin
virus
display
vaccinemedi
enhanc
viru
replic
enhanc
patholog
vrp
vaccin
induc
broad
neutral
antibodi
respons
like
target
multipl
epitop
across
glycoprotein
possibl
note
enhanc
infect
monoclon
antibodi
nullifi
inde
recent
work
show
antibodi
specif
rbd
glycoprotein
reproduc
enhanc
infect
pseudotyp
virus
bear
identifi
conserv
epitop
allow
three
strain
effect
neutral
rais
hope
singl
vaccin
could
effect
wide
diverg
strain
sarscov
clearli
addit
studi
need
heterolog
strain
altern
anim
model
possibl
vaccineinduc
enhanc
infect
patholog
discount
knowledg
studi
first
demonstr
sarscov
vaccin
confer
longterm
protect
period
host
suscept
sarscov
patholog
senesc
furthermor
vrp
vaccin
young
anim
protect
challeng
diverg
strain
sarscov
indic
current
vaccin
may
also
provid
protect
mani
zoonot
strain
might
emerg
futur
cross
protect
observ
among
vaccin
ha
formul
influenza
viru
vrp
vaccin
noroviru
induc
robust
immun
respons
older
anim
challeng
vrp
vector
provid
protect
challeng
without
enhanc
patholog
induc
vrpn
vaccin
human
infect
report
sinc
anim
model
essenti
develop
sarscov
vaccin
young
mous
model
provid
readili
avail
anim
homogen
genet
background
effici
replic
within
respiratori
tract
senesc
mous
model
add
benefit
enhanc
pathogenesi
mimick
agerel
suscept
seen
human
although
age
decreas
b
cell
immun
innat
immun
function
human
mice
character
immun
defici
incomplet
speci
sarscov
infect
senesc
mice
provid
key
model
evalu
mechan
age
deter
immun
respons
highli
pathogen
emerg
virus
like
sarscov
influenza
viru
develop
key
intervent
approach
enhanc
vaccin
efficaci
elderli
expens
limit
avail
senesc
speci
make
mous
model
invalu
import
caveat
must
consid
evalu
work
murin
model
sar
diseas
limit
diseas
progress
mice
faster
human
rodent
human
share
symptom
viru
infect
less
sever
limit
also
evid
hamster
primat
ferret
model
shortcom
necessit
vaccin
candid
test
anim
system
underscor
critic
need
develop
highli
pathogen
challeng
model
vaccin
therapeut
test
report
provid
mechan
patholog
provid
solut
minim
potenti
risk
associ
although
passiv
transfer
serum
reproduc
inflamm
seen
anim
result
must
interpret
caution
antin
antibodi
level
recipi
mice
lower
mice
directli
immun
vrpn
data
present
manuscript
reveal
critic
need
potenti
complic
vaccin
design
lay
foundat
continu
futur
studi
improv
qualiti
safeti
efficaci
sarscov
vaccin
model
system
provid
mean
identifi
host
factor
contribut
immun
senesc
allow
us
evalu
whether
chang
vaccin
design
regimen
improv
vaccin
efficaci
senesc
anim
model
provid
clear
ration
test
candid
sar
vaccin
hamster
ferret
primat
model
patholog
clinic
diseas
promin
follow
wildtyp
viru
challeng
research
provid
model
futur
experi
design
character
compon
induc
pulmonari
inflamm
suggest
vaccin
regimen
contain
n
protein
use
caution
human
popul
test
success
resurrect
novel
recombin
sar
challeng
viru
bear
zoonot
glycoprotein
suggest
might
feasibl
reconstruct
rare
zoonot
sarscov
never
success
cultur
provid
novel
challeng
virus
vaccin
therapeut
drug
test
potenti
futur
zoonot
sar
introduct
human
popul
final
studi
encourag
develop
senesc
anim
model
human
diseas
encourag
vaccin
test
design
influenza
west
nile
viru
pathogen
produc
disproportion
diseas
burden
elderli
